Article Per Year (5 Year)
p-Index From 2019 - 2024
0
P-Index
This Author published in this journals
All Journal Ophthalmologica Indonesiana Ophthalmologica Indonesiana
Cut Putri Samira
Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta
Health Professions Medicine & Pharmacology Physics Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Efficacy and Safety of Imiquimod 5% as Primary Therapy in Management of Nodular Basal Cell Carcinoma of the Eyelid Cut Putri Samira; Rossalyn Sandra Andrisa
Majalah Oftalmologi Indonesia Vol 42 No 2 (2016): Ophthalmologica Indonesiana
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/journal.v42i2.80

Abstract

Background: To evaluate the efficacy (complete resolution, tolerability, and recurrance of BCC) andsafety (adverse effect during and after treatment) of imiquimod 5% cream as primary therapy inmanagement of nodular basal cell carcinoma.Methods: Journal articles published that were published between 2007 and 2011 related to themanagement of eyelid nodular basal cell carcinoma with imiquimod 5% cream were reviewed.Results: Of all 6 articles: 1 article was randomized trial study; 1 article was case series study; whilethe others were prospective studies. The rate of complete resolution with imiquimod 5% therapy wasoverall high with range 80-100% between all studies. Four studies reported tolerability of imiquimodtherapy assessed by ophthalmologist also range from 80-100%. No occurance of relapse were reportedin all studies. Skin reaction is the most common adverse effect seen with the rate widely variedbetween 53.5% to 100%. Skin reaction could be seen as erythema, crusting, or scabbing in the site ofimiquimod application during and after treatment of the therapy. The other side effects were skinulceration (40-55.5%), keratitis (15%), conjunctivitis (13.3-40%), and ocular discomfort (60%). Nosystemic side effect were reported in all studies.Conclusion: Imiquimod 5% cream gains good evidence of efficacy and safety in treating nodular eyelidand periocular BCC. Imiquimod may be used as first-line treatment in patients with small eyelidnodular BCC located in patients who refuse surgery or have existing pathologies that contraindicatesurgery.Keywords: imiquimod 5% cream, basal cell carcinoma of the eyelid or periocular
Efficacy and Safety of Imiquimod 5% as Primary Therapy in Management of Nodular Basal Cell Carcinoma of the Eyelid Cut Putri Samira; Rossalyn Sandra Andrisa
Majalah Oftalmologi Indonesia Vol 42 No 2 (2016): Ophthalmologica Indonesiana
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/journal.v42i2.80

Abstract

Background: To evaluate the efficacy (complete resolution, tolerability, and recurrance of BCC) andsafety (adverse effect during and after treatment) of imiquimod 5% cream as primary therapy inmanagement of nodular basal cell carcinoma.Methods: Journal articles published that were published between 2007 and 2011 related to themanagement of eyelid nodular basal cell carcinoma with imiquimod 5% cream were reviewed.Results: Of all 6 articles: 1 article was randomized trial study; 1 article was case series study; whilethe others were prospective studies. The rate of complete resolution with imiquimod 5% therapy wasoverall high with range 80-100% between all studies. Four studies reported tolerability of imiquimodtherapy assessed by ophthalmologist also range from 80-100%. No occurance of relapse were reportedin all studies. Skin reaction is the most common adverse effect seen with the rate widely variedbetween 53.5% to 100%. Skin reaction could be seen as erythema, crusting, or scabbing in the site ofimiquimod application during and after treatment of the therapy. The other side effects were skinulceration (40-55.5%), keratitis (15%), conjunctivitis (13.3-40%), and ocular discomfort (60%). Nosystemic side effect were reported in all studies.Conclusion: Imiquimod 5% cream gains good evidence of efficacy and safety in treating nodular eyelidand periocular BCC. Imiquimod may be used as first-line treatment in patients with small eyelidnodular BCC located in patients who refuse surgery or have existing pathologies that contraindicatesurgery.Keywords: imiquimod 5% cream, basal cell carcinoma of the eyelid or periocular
Co-Authors Rossalyn Sandra Andrisa